ISSN: 1464-2662

Journal Home

Journal Guideline

HIV Medicine Q1 Unclaimed

Wiley-Blackwell Publishing Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

HIV Medicine is a journal indexed in SJR in Infectious Diseases and Health Policy with an H index of 86. It has a price of 2500 €. It has an SJR impact factor of 1,052 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,052.

HIV Medicine focuses its scope in these topics and keywords: hiv, hivinfected, care, hepatitis, virus, risk, cohort, adults, highrisk, individuals, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Health Policy (Q1) Infectious Diseases (Q1) Pharmacology (medical) (Q1)

Price

2500 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,052

SJR Impact factor

86

H Index

151

Total Docs (Last Year)

348

Total Docs (3 years)

5203

Total Refs

911

Total Cites (3 years)

321

Citable Docs (3 years)

2.64

Cites/Doc (2 years)

34.46

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Reviews Microbiology Q1
Clinical Microbiology Reviews Q1
The Lancet Infectious Diseases Q1
Cellular and Molecular Immunology Q1
Drug Resistance Updates Q1

Compare this journals

Aims and Scope

Best articles by citations

O1 Compartmentalization of resistance mutations in HIV-1 between the lung and peripheral blood

O18 A dichotomy in CD4 T-cell responses specific to HIV antigens

HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV

O19 CD4+ T-cell responses in early HIV infection

P6 Demographics of 100 people testing HIV positive in the Royal Free Hospital in the preand post-HAART era

Paediatric antiretroviral therapy audit in South London

O4 A novel point mutation assay for the detection of resistance to non-nucleoside reverse transcriptase inhibitors

O6 Genotypic resistance mutations and virological response to combination therapy in a clinical cohort

P8 The effect of demographic and clinical factors on the natural history of viral load in HIV infection

Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy, 1999-2009

O7 Structural solution of the HIV-1 packaging signal and use of RNA transcripts containing the signal as potential antiviral molecules

O8 HIV post-exposure prophylaxis (PEP): a retrospective review

SHOW MORE ARTICLES

Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy

P21 Prevalence of antiretroviral resistance mutations in treatment-naive HIV-1-infected patients in South London

Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population

Disseminated infection due to Encephalitozoon cuniculi in a patient with AIDS: case report and review

Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up

010 Quadruple HAART in primary infection: results from QUEST

011 The viral response to HAART over the first 16 weeks of therapy according to the pre-HAART and the 4-8-week viral load

012 AIDS-related lymphoma in the era of HAART

013 Normalization of intestinal permeability following antiretroviral therapy in HIV+ patients with diarrhoea

014 Does TB treatment alter virological and immunological response to HAART?

015 Rapid onset lipodystrophy syndrome (LD) in three patients with prior severe nucleoside toxicity

016 Type III hyperlipidaemia, related to PI treatment, is not caused by homozygosity for apoE2